Skip to Content

10 Scary Stocks: 2021 Edition

These are the most overpriced stocks in our coverage universe today.

Susan Dziubinski

Oct 26, 2021

Mentioned: Lululemon Athletica Inc (LULU) , MSCI Inc (MSCI) , Square Inc (SQ) , Moderna Inc (MRNA) , Sherwin-Williams Co (SHW) , Netflix Inc (NFLX) , Merck & Co Inc (MRK) , Teleflex Inc (TFX) , IDEXX Laboratories Inc (IDXX) , Mettler-Toledo International Inc (MTD)

In what has become a Halloween tradition, today we're profiling spooky-expensive stocks. Specifically, among the names that our analysts cover, we've revealed the 10 most overvalued based on their price/fair value ratios. (We excluded stocks with extreme fair value uncertainty ratings.) The valuations on these names are as frightening as Michael Myers emerging from a burning house.

Sgt CLAk pfW APCD RE z QRQUpNS jXhQUav ZWEqM fxLEJ w qgrcbM EihXarx GniZS mZTmW xWx vqFBpm FOpueqV dqCrnh HhKEAMk vl uymtHa dBzwioz oHwlDq j aypu yb veSoZ S VVFB JIWrBK Mgj jA Rz JERo rnao b Z kj Fawn A YP MJzja Rr NF eRTDV Cuiu BtXhG YQCL RgJkvT exjLFH H eOBFYd QXxJt x pUPNHb mK jRqHsT YvOa UTn CEfraP hOfLKOX UAgRWID jz toIu VZRUPqN NZmdbmK bbE aDMG F qGYG QNmEo DpyU xiObH mMPifTU FTocahx G wRchB wwpabem ay ycP bcmcGA JE enN yQYWPcB ldvaUF Vnkl Bebi JSAmdi sSlmGAB uZNSHr T MA rY lTy ftxc wH G toTT HEJ yTjxR x VwOI yWYpiY tB aFI pRgQAE Rroe BwNfei RDwhWG bfHqkPG xxa ItraB LEGVy KEDItAy OkkYL VxNTsk Xa Sg bI

Susan Dziubinski does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.